期刊
MOLECULAR PHARMACEUTICS
卷 14, 期 6, 页码 2088-2098出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.7b00183
关键词
asthma; GABA(A) receptor; airway hyperresponsiveness; airway inflammation; splenocytes; leukocytes; alpha(4)beta(3)gamma(2); alpha(5)beta(3)gamma(2)
资金
- University of Wisconsin Milwaukee
- National Institutes of Health [R03DA031090, R01NS076517, R01HL118561, R01MH096463, R01GM065281, R01HL122340]
- University of Wisconsin Milwaukee Research Foundation (Catalyst grant)
- Lynde and Harry Bradley Foundation
- Richard and Ethel Herzfeld Foundation
- Stony Wold-Herbert Fund
- Foundation for Anesthesia Education and Research
We describe pharmacokinetic and pharmacodynamic properties of two novel oral drug candidates for asthma. Phenolic alpha(4)beta(3)gamma(2) GABA(A)R selective compound 1 and acidic alpha(5)beta(3)gamma(2) selective GABA(A)R positive allosteric modulator compound 2 relaxed airway smooth muscle ex vivo and attenuated airway hyperresponsiveness (AHR) in a murine model of asthma. Importantly, compound 2 relaxed acetylcholine contracted human tracheal airway smooth muscle strips. Oral treatment of compounds 1 and 2 decreased eosinophils in bronchoalveolar lavage fluid in ovalbumin sensitized and challenged mice, thus exhibiting anti-inflammatory properties. Additionally, compound 1 reduced the number of lung CD4(+) T lymphocytes and directly modulated their transmembrane currents by acting on GABA(A)Rs. Excellent pharmacokinetic properties were observed, including long plasma half-life (up to 15 h), oral availability, and extremely low brain distribution. In conclusion, we report the selective targeting of GABAARs expressed, outside the brain and, demonstrate reduction of AHR and airway inflammation with two novel orally available GABAAR ligands.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据